Cytokinetics announced that CareMed, an independent specialty pharmacy, will serve as a pharmacy partner for its newly approved cardiac myosin inhibitor MYQORZO (aficamten). The partnership will allow CareMed to dispense MYQORZO to patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and to manage the drug’s Risk Evaluation and Mitigation Strategy (REMS) program and patient‑support services.
MYQORZO received U.S. FDA approval on December 19, 2025, and is slated for commercial availability in the second half of January 2026. The drug is an allosteric, reversible inhibitor of cardiac myosin motor activity that reduces left‑ventricular outflow tract obstruction and improves exercise capacity in adults with oHCM. The FDA approval was based on the positive results of the Phase 3 SEQUOIA‑HCM trial, which demonstrated significant symptom relief compared with placebo.
CareMed’s selection is strategic because the company has a proven track record of managing REMS programs for high‑risk therapies and of delivering comprehensive patient‑support services. By leveraging CareMed’s specialty‑pharmacy infrastructure, Cytokinetics can ensure rapid, compliant distribution of MYQORZO to cardiology practices and patients across the United States, thereby accelerating market penetration and adoption of the first‑in‑class therapy.
The U.S. oHCM market is estimated to include more than 300,000 diagnosed patients, and MYQORZO competes with Bristol Myers Squibb’s Camzyos. Cytokinetics’ CEO, Robert I. Blum, highlighted that MYQORZO offers a safer, easier‑to‑use profile and unique pharmacokinetics that may give it a competitive edge in a market that is shifting toward disease‑modifying treatments.
Blum stated, “Our first FDA approval confirms the strength of our science and the bold, trailblazing research that has defined Cytokinetys’ leadership in muscle biology. The partnership with CareMed positions us to deliver MYQORZO efficiently to patients who need it most.”
The partnership is expected to accelerate sales velocity, broaden the drug’s reach, and support Cytokinetics’ goal of capturing a substantial share of the U.S. oHCM market as the company moves from regulatory approval to commercial launch.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.